The Role of Stop-Loss Insurance and Reinsurance in Managing Performance-Based Agreements

Eric NormanFoCUS, Whitepapers

Over the last decade, rising healthcare costs and the availability of expensive new treatment options has led to a substantial increase in the number of patients with large insurance claims. … Read More

State Insurance Regulations Regarding Benefit Design (Deductible and Co-Pay Waivers)

Eric NormanFoCUS, Research Briefs

FoCUS has identified an issue that may be a barrier to timely patient access to durable therapies. The advent of expensive, one-time durable therapies will require changes in private payer … Read More

NEWDIGS turns 10!

Eric NormanFoCUS, LEAPS, News

NEWDIGS turns 10: Birthday cake with 10 candles

Letter from Dr Gigi Hirsch Executive Director, MIT Center for Biomedical Innovation and Director, NEWDIGS In 2009 an international working group of biomedical research and healthcare leaders gathered at MIT … Read More

Payer Perspectives Survey

Eric NormanFoCUS, Research Briefs

A survey of 77 payers representing over 280 million lives, completed in April 2019, explored perspectives concerning financing challenges and management strategies associated with durable cell and gene therapies. Download … Read More

Pediatric Gene Therapy Launches

Eric NormanFoCUS, Research Briefs

Gene therapy cures for hereditary genetic conditions are likely to reach the United States market in the coming decades. Several disease areas with potential cures are orphan conditions, which affect … Read More

Patient & Caregiver Themes Survey

Eric NormanFoCUS, Research Briefs

Patients and caregivers are key stakeholders in the development of system-wide, implementable precision financing models for durable and curative therapies. Patient and caregiver challenges are generally assumed to be primarily … Read More

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Eric NormanFoCUS, News

Paying for Cures Conference, February 12, 2019

American Journal of Managed Care Curative therapies represent a conundrum for healthcare. On the one hand, there is the ability to cure patients of potentially life-threatening diseases or diseases that … Read More